Miromatrix Medical Inc

Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. It offers perfusion decellularization and recellularization technology, as well as organ-derived biological products such as MIROMESH and MIRODERM for soft tissue reinforcement and advanced wound care. The company was founded in 2009 by Doris A. Taylor and Cohen Robert and is headquartered in Eden Prairie, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Miromatrix Medical is a biotechnology company engaged in the development of fully biological human organs and organ-derived biological products to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization or recellularization technology, as well as organ-derived biological products for applications such as soft tissue reinforcement and advanced wound care.  It was founded in 2009 and is based in Eden Prairie, Minnesota.

EDEN PRAIRIE, Minn., April 10, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that CEO Jeff Ross, Ph.D will present at the 2023 Cell & Gene Meeting on the Mediterranean. The conference will be held April 12 – 14 in Barcelona, Spain, bringing together leading public and private sector cell and gene therapy companies.

Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Med

CareDx

BRISBANE, Calif. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q4 2022 Earnings Conference Call March 31, 2023 4:30 PM ET Company Participants Hannah Jeffrey - Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Phillip Dantoin - Piper Sandler Alex Nowak - Craig-Hallum Capital Group Operator Greetings and welcome to the Miromatrix Medical, Inc. Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Miromatrix Medical Inc. (MIRO) Q4 2022 Earnings Call Transcript

Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 10.81% and 9,200%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Miromatrix Medical Inc. (MIRO) Reports Q4 Loss, Tops Revenue Estimates

EDEN PRAIRIE, Minn., March 31, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported fourth quarter and full year 2022 financial results and provided a corporate update.

Miromatrix Reports Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., March 15, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the fourth quarter and full year 2022 after market close on Friday, March 31, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Fourth Quarter and Full Year 2022 Financial Results

Miromatrix Medical (NASDAQ: MIRO ) stock is falling on Wednesday after the life sciences company priced shares for a public offering. That public offering has Miromatrix Medical selling 6,250,000 shares of MIRO stock for a price of $1.60 each.

Why Is Miromatrix Medical (MIRO) Stock Down 41% Today?

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $1.60 per share, before underwriting discounts and commissions. The gross proceeds to Miromatrix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Miromatrix are expected to be $10.0 million. The offering is expected to close on March 10, 2023, subject to customary closing conditions. Additionally, Miromatrix has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Miromatrix. Piper Sandler & Co. is acting as the book-running manager and Craig-Hallum is acting as the lead manager for the offering.

Miromatrix Medical Inc. Announces Pricing of $10 Million Public Offering of Common Stock

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Miromatrix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by Miromatrix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Miromatrix Medical Inc. Announces Proposed Public Offering of Common Stock

NEW YORK , Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. ("Miromatrix" or the "Company") (NASDAQ: MIRO). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Baxter

EDEN PRAIRIE, Minn. & DEERFIELD, Ill.--( BUSINESS WIRE )--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter's PrisMax system. Miromatrix submitted an Investigational New Drug (IND) application for miroliverELAP to the U.S. Food and Drug Administration (FDA) in November 2022, which appears to be the first IND for a bioengineered organ. Miromatrix intends to commence a Phase I clinical trial using miroliverELAP to treat patients suffering from ALF, following FDA's decision that the trial may proceed. Baxter is both a collaborator and shareholder of Miromatrix.

Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

EDEN PRAIRIE, Minn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today provided a program update on miroliverELAP™.

Miromatrix Provides Update on miroliverELAP

Shares of Miromatrix Medical Inc. were down about 33% in premarket trading on Thursday, the day after the company said there's a clinical hold on its experimental acute liver failure treatment. Miromatrix had submitted the investigational new drug application for the therapy to the Food and Drug Administration last month.

Miromatrix's stock is down 33%

EDEN PRAIRIE, Minn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it was informed via e-mail from the U.S. Food and Drug Administration (FDA) that the miroliverELAP tm Investigational New Drug (IND) application for the treatment of acute liver failure has been placed on clinical hold. The miroliverELAP IND application was submitted in mid-November. The FDA indicated they will provide an official clinical hold letter to Miromatrix within 30 days. Miromatrix plans to provide additional updates pending communication with the FDA.

Miromatrix Announces FDA Clinical Hold on IND Application for miroliverELAP

EDEN PRAIRIE, Minn., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference on December 1st, 2022.

Miromatrix Announces Participation in the Piper Sandler 34th Annual Healthcare Conference

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Hannah Jeffrey - IR Jeff Ross - CEO Jim Douglas - CFO Operator Greetings, and welcome to the Miromatrix Medical Inc.'s Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Miromatrix Medical Inc. (MIRO) Q3 2022 Earnings Call Transcript

EDEN PRAIRIE, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2022 financial results and provided a corporate update.

Miromatrix Reports Filing of IND, Third Quarter 2022 Results, and Provides Corporate Update

EDEN PRAIRIE, Minn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the third quarter 2022 after market close on Monday, November 14, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Third Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will be a keynote speaker at BioFabUSA's 2022 Fall Summit from the Advanced Regenerative Manufacturing Institute (ARMI).

Miromatrix CEO Jeff Ross Delivering Keynote Address at ARMI | BioFabUSA 2022 Fall Summit: Meeting in the Millyard

EDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mesa. The three day event held this year on October 11-13 features in-person and pre-recorded virtual presentations by leading public and private companies highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and regenerative medicine.

Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa

EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event. The two-day virtual event held this year on September 28-29, will focus the first day on solid organ transplant (SOT), in particular, kidney transplants, and the second day on the unmet need and innovations in hematopoietic stem cell transplant (HSCT).

Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

EDEN PRAIRIE, Minn., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Bioregate European Regenerative Medicine Forum. The conference, held this year on September 21-23 in Louvain-la-Neuve, Belgium, is dedicated to the 4R Medicine, Repair, Replacement, Regeneration, and Reprogramming.

Miromatrix CEO Jeff Ross to Present at the Bioregate European Regenerative Medicine Forum

EDEN PRAIRIE, Minn., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a new patent from the United States Patent and Trademark Office for its perfusion decellularization and recellularization technology. This new patent further expands the Company's extensive patent portfolio covering the bioengineering of transplantable organs.

Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology

EDEN PRAIRIE, Minn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the company will participate in the Gilmartin Emerging Growth Company Showcase on August 31st, 2022.

Miromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company Showcase

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Hannah Jeffrey - Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Operator Greetings, and welcome to Miromatrix Medical Inc.'s Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

News for Miromatrix Medical Inc Stock (MIRO)